熱門資訊> 正文
萨雷普塔任命迈克尔·塞韦里诺为首席执行官
2026-07-27 20:40
- Sarepta Therapeutics (SRPT) has appointed Michael Severino as chief executive officer, effective July 28, 2026.
- Severino, the former CEO of Tessera Therapeutics, will also join Sarepta's board of directors. He succeeds Doug Ingram, who is retiring and will remain with the company in an advisory role through the end of 2026 to support the leadership transition
- Severino brings more than 25 years of biopharmaceutical industry experience, including serving as vice chairman and president of AbbVie, where he oversaw research and development as well as the company's corporate strategy office.
- SRPT shares rose 7% premarket to $16.7.
More on Sarepta Therapeutics
- Sarepta: Caution Still Warranted Despite FDA's Gene Therapy-Friendly Stance
- Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
- Sarepta reiterates $1.2B-$1.4B 2026 net product revenue guidance while targeting Cohort 8 data by year-end
- Sarepta turns negative despite Q1 beats; 2026 guidance maintained
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
